AN2 Therapeutics (ANTX) Operating Expenses (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Operating Expenses data on file, last reported at $10.6 million in Q1 2026.

• On a quarterly basis, Operating Expenses fell 8.55% year-over-year to $10.6 million in Q1 2026; TTM through Mar 2026 was $37.1 million, a 25.8% decrease from a year earlier, with the FY2025 full-year figure at $38.1 million, down 32.89% from the prior year.
• Operating Expenses for Q1 2026 stood at $10.6 million, up from $9.3 million in the prior quarter.
• Over the last five years, Operating Expenses for ANTX reached as high as $18.8 million in Q4 2023 and fell as low as $7.2 million in Q2 2025.
• Historically, Operating Expenses has averaged $12.8 million across 5 years, with a median of $11.8 million in 2022.
• Across the five-year window, Operating Expenses jumped 274.78% in 2022 and tumbled 54.56% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $12.5 million in 2022, then jumped by 50.81% to $18.8 million in 2023, then slumped by 54.3% to $8.6 million in 2024, then rose by 8.35% to $9.3 million in 2025, then climbed by 13.26% to $10.6 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $10.6 million in Q1 2026, $9.3 million in Q4 2025, and $10.0 million in Q3 2025.